SCHEMBL23342149

SCHEMBL23342149

CC(C)C(=O)N1CCCCC(C(=O)N(C)C(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
LMNA P02545 1/20 0.36
MMP1 P03956 3/20 0.35
MMP2 P08253 3/20 0.35
MMP3 P08254 3/20 0.35
MMP8 P22894 3/20 0.35
MMP13 P45452 3/20 0.35
GAA P10253 2/20 0.34
DPP4 P27487 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KCNH2 Q12809 1/20 0.34
DPP8 Q6V1X1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23342020 0.95 CHRNB2 (0.37) HPGDALDH1A1TSHRCHRNB2CHRNA3
SCHEMBL25895221 0.89 MEN1 (0.40) ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL25919918 0.83 BCHE (0.47) HPGDALDH1A1CHRNB2CHRNA3CHRNA4
SCHEMBL25920084 0.83 MEN1 (0.43) HPGDALDH1A1TSHRGAACYP2C9
SCHEMBL25895224 0.82 CHRNB2 (0.47) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL27283733 0.81 DPP4 (0.46) ALDH1A1GAADPP4CYP2C9CYP2C19
SCHEMBL25895223 0.80 MEN1 (0.41) ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL1911777 0.79 CES2 (0.42) ALDH1A1TSHRSMN1; SMN2
SCHEMBL12375165 0.77 CES2 (0.39) TSHRGAAMEN1KMT2ASMN1; SMN2
SCHEMBL25912481 0.76 MEN1 (0.45) ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
US-20210130326-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739074-B2 Ras inhibitors KRAS, NRAS, HRAS HPGD 2601/4885ALDH1A1 3951/4885TSHR 3396/4885
US-20210130326-A1 RAS INHIBITORS KRAS, NRAS, HRAS HPGD 3002/4885ALDH1A1 4437/4885TSHR 3332/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR HPGD 3593/4885ALDH1A1 4528/4885TSHR 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.